CytoDyn shareholders approve increase in authorized shares to 2.25B; all directors reelected

CytoDyn Inc.

Authorized common stock increased from 1.75B to 2.25B shares; approved 671,591,768 For vs 69,716,006 Against.
All five director nominees elected: Tanya Urbach, Stephen Simes, Ryan Dunlap, Lishomwa Ndhlovu, Karen Brunke.
Advisory vote on executive compensation passed with 389,864,422 For, 108,351,482 Against.
Shareholders ratified CBIZ CPAs as auditor for FY ending May 31, 2026; vote 721,348,317 For.
Advisory vote on frequency of say-on-pay set at one year; 451,446,382 votes for one year.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CytoDyn Inc.: Amended certificate of incorporation to increase authorized shares of common stock from 1,750,000,000 to 2,250,000,000 (effective 2025-11-21).

Change: charter amendment
Effective: 2025-11-21

Exact text from the filing

On November 21, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation, increasing the total number of authorized shares of common stock, par value $0.001 per share, from 1,750,000,000 to 2,250,000,000.

View on SEC.gov

269 governance changes filed in the last 30 days. Browse all governance changes →

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-115056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.